TrippBio
OperatingTrippBio, Inc
Healthcare · Founded 2020
TrippBio is developing a new, therapeutic application of an FDA-approved drug with a high probability to be proven safe and efficacious in the treatment and prevention of the SARS-CoV-2 virus that causes COVID-19.
Financials
FY2018–FY2023 (no data for FY2021) · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inBlue bars are the pre-money valuation the company stated for a priced round.
Share price over rounds
“Today's shares” restates every price in the share terms current now, so a price before a split or an LLC→corporation conversion is divided by that event's ratio (each event is cited on the round page). Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines.
Cap table
Principal holders% as the filing states it, Oct 28, 2024
- William Meadow470,800 Series A Stock100.0%of company
- William Meadow7,062,000 Common Stock12.1%of company
Sold to the crowd
- Reg CF · Sep 20201,015,542 shares at $0.1818 in today's terms · sold as 46,161 shares at $4.00; since then a 22-for-1 split (Oct 2022)$184.6K
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
3 peopleNames and titles as disclosed on SEC Form C. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 2 of 6 annual reports (FY2020–FY2025)
Missing: 2021, 2022, 2024, 2025
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 10 filings on EDGAR- Form C-UFeb 24, 20250001665160-25-000299EDGAR
- Form CNov 13, 20240001665160-24-001603EDGAR
- Form C-AROct 28, 20240001665160-24-001481EDGAR
- Form DDec 1, 20220001096906-22-002885EDGAR
- Form C-ARJul 20, 20210001669191-21-000709EDGAR
- Form C-UMar 10, 20210001669191-21-000248EDGAR
- Form C/ADec 9, 20200001669191-20-000788EDGAR
- Form C/ANov 12, 20200001669191-20-000659EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.